Sign in

Private company

Harpoon Therapeutics, Inc.

American biological products company based in South San Francisco2

In its 2023 annual report the company says: “We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. We are developing a pipeline of novel T cell engagers initially focused on the treatment of solid tumors and hematologic malignancies.”68

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address611 Gateway Boulevard, Suite 400, South San Francisco, Ca 940803
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300VFZL0TEVXILA362
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57134682

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-214.1%Operating margin4
-212.2%Net margin4
34.9%Revenue growth, 20224
-1254.5%Return on equity4
-$89.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$81.4M

Out of $31.9M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$31.9M in 2022+4408% since 2017
0$10.0M$20.0M$30.0M$40.0M2017: $708.0K$708.0K20172018: $4.8M$4.8M2018+571%2019: $5.8M$5.8M2019+22%2020: $17.4M$17.4M2020+202%2021: $23.7M$23.7M2021+36%2022: $31.9M$31.9M2022+35%
Operating income85674-$68.3M in 2022+513% since 2016
-$150.0M-$100.0M-$50.0M02016: -$11.1M-$11.1M20162017: -$16.5M-$16.5M2017+48%2018: -$27.7M-$27.7M2018+68%2019: -$58.2M-$58.2M2019+110%2020: -$51.3M-$51.3M2020−12%2021: -$116.8M-$116.8M2021+127%2022: -$68.3M-$68.3M2022−41%
Net income85674-$67.7M in 2022+494% since 2016
-$150.0M-$100.0M-$50.0M02016: -$11.4M-$11.4M20162017: -$16.8M-$16.8M2017+48%2018: -$27.4M-$27.4M2018+63%2019: -$55.6M-$55.6M2019+103%2020: -$49.9M-$49.9M2020−10%2021: -$116.7M-$116.7M2021+134%2022: -$67.7M-$67.7M2022−42%
Fiscal year2016201720182019202020212022
Revenue$708.0K5$4.8M6$5.8M7$17.4M4$23.7M4$31.9M4
Research and development$7.8M8$13.6M5$26.4M6$41.6M7$52.6M4$72.1M4$81.4M4
Operating expenses$140.4M4$100.2M4
Operating income-$11.1M8-$16.5M5-$27.7M6-$58.2M7-$51.3M4-$116.8M4-$68.3M4
Interest$261.0K8$285.0K5
Income tax$08$05$07$04$04$04
Net income-$11.4M8-$16.8M5-$27.4M6-$55.6M7-$49.9M4-$116.7M4-$67.7M4
Earnings per share-$1.994-$3.624-$2.044
Earnings per share (diluted)-$1.994-$3.624-$2.044
Shares (weighted, basic)32.3M shares433.2M shares4
Shares (weighted, diluted)32.3M shares433.2M shares4

Compare Harpoon Therapeutics, Inc. with another company

Corporate structure

Harpoon Therapeutics, Inc. is part of a group headed by Merck & Co.. 347 entities, 69 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Harpoon Therapeutics, Inc.

  • Merck & Co. Rahway, New Jersey, United States
    • Harpoon Therapeutics, Inc. South San Francisco, California, United States
    • MSD Sharp & Dohme GmbH München, Germany
    • Merck (Japan) Subsidiary · Tokyo, Japan
    • Merck Sharp & Dohme Latvija, SIA Subsidiary · Riga, Latvia
    • Merck Sharp & Dohme, UAB Subsidiary · Vilnius, Lithuania
    • MSD (Netherlands) Subsidiary · Amsterdam, Netherlands
    • MSD Norway AS Subsidiary · Drammen, Norway
    • Sirna Therapeutics Subsidiary · San Francisco
    • 7728026 Canada Inc. Subsidiary · Canada
    • Abceutics, Inc. Subsidiary · Delaware, United States
    • Abmaxis Inc. Subsidiary · Delaware, United States
    • Acceleron Pharma Inc. Subsidiary · Delaware, United States
    • Afferent Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Agrident GmbH Subsidiary · Germany
    • Allflex (China) Intelligent Technology Co. Ltd. Subsidiary · China
    • Allflex Argentina S.A. Subsidiary · Argentina
    • Allflex Australia Pty. Ltd. Subsidiary · Australia
    • Allflex Dan-Mark ApS Subsidiary · Denmark
    • Allflex Europe S.A.S. Subsidiary · France
    • Allflex Group Germany GmbH Subsidiary · Germany
    • ALLFLEX INDIA PRIVATE LIMITED Subsidiary · Gurugram, India
    • Allflex Maroc S.A.R.L. Subsidiary · Morocco
    • Allflex New Zealand Subsidiary · New Zealand
    • Allflex Polska Spolka z ograniczona odpowiedzialnoscia Subsidiary · Poland
    • Allflex Romania S.R.L. Subsidiary · Romania
    • and 316 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Harpoon Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$15.8M4 Dec 31, 2022$15.4M4 Dec 31, 2021+2.2%
Accumulated depreciation$8.5M4 Dec 31, 2022$6.2M4 Dec 31, 2021+38.1%
Property and equipment, net$7.2M4 Dec 31, 2022$9.2M4 Dec 31, 2021−21.7%
Operating-lease assets (leased space)$10.9M4 Dec 31, 2022$6.1M4 Dec 31, 2021+77.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$51.6M4 Dec 31, 2022$44.7M4 Dec 31, 2021+15.5%
Marketable securities, current$1.5M4 Dec 31, 2022$90.4M4 Dec 31, 2021−98.3%
Marketable securities, non-current$04 Dec 31, 2022$1.5M4 Dec 31, 2021−100.0%
Debt securities available for sale$47.5M4 Dec 31, 2022$134.8M4 Dec 31, 2021−64.8%

Leadership

Who has led Harpoon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gerald McMahon Phd.2019–2021
  2. Julia Marie Eastland2021–2024

President

  1. Gerald McMahon Phd.2019–2021
  2. Julia Marie Eastland2021–2024

Chief financial officer

  1. Georgia Erbez2019–2022
20202025
Board members and other officers (18)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorJulie Eastland named Apr 7, 2023 to Oct 31, 202330
  • DirectorJonathan Drachman named Apr 7, 2023 to Oct 31, 202330
  • DirectorRonald Hunt named Apr 7, 2023 to Oct 31, 202330

Timeline

  1. Mar 11, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer31
  2. Mar 8, 20248-K Shareholder vote32
  3. Feb 28, 20248-K Other events33
  4. Feb 22, 20248-K Other events34
  5. Jan 29, 20248-K Bylaws or fiscal year changed35
  6. Jan 26, 20248-K Other events36
  7. Jan 8, 20248-K Entered a material agreement; Executive or director change; Regulation FD disclosure37
  8. Nov 28, 20238-K Executive or director change38
  9. Nov 24, 20238-K Other events39
  10. Nov 9, 20238-K Results of operations40
  11. Oct 24, 20238-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights41
  12. Oct 23, 20238-K Other events42
  13. Nov 9, 2021New chief executive Julia Marie Eastland becomes CEO11
  14. Feb 7, 2019New chief executive Gerald McMahon Phd. becomes CEO12

Calendar

When it reported results

  1. Nov 9, 2023Reported quarterly or annual results40
  2. Aug 9, 2023Reported quarterly or annual results43
  3. May 12, 2023Reported quarterly or annual results44
  4. Mar 27, 2023Reported quarterly or annual results45
  5. Nov 14, 2022Reported quarterly or annual results46
  6. Aug 10, 2022Reported quarterly or annual results47
  7. May 12, 2022Reported quarterly or annual results48
  8. Mar 10, 2022Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

203 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 34 major events, 79 insider forms, 31 large holders, 2 private raises, 48 other. The latest 20:

  1. Mar 21, 202415-12G EDGAR
  2. Mar 18, 2024SC 13G EDGAR
  3. Mar 13, 2024SC 13D/A EDGAR
  4. Mar 11, 2024EFFECT EDGAR
  5. Mar 11, 2024EFFECT EDGAR
  6. Mar 11, 2024EFFECT EDGAR
  7. Mar 11, 2024SC 13D/A EDGAR
  8. Mar 11, 2024POS AM EDGAR
  9. Mar 11, 2024POS AM EDGAR
  10. Mar 11, 2024POS AM EDGAR
  11. Mar 11, 2024S-8 POS EDGAR
  12. Mar 11, 2024S-8 POS EDGAR
  13. Mar 11, 2024S-8 POS EDGAR
  14. Mar 11, 2024S-8 POS EDGAR
  15. Mar 11, 2024S-8 POS EDGAR
  16. Mar 11, 2024S-8 POS EDGAR
  17. Mar 11, 2024S-8 POS EDGAR
  18. Mar 11, 20248-K EDGAR
  19. Mar 11, 20244 EDGAR
  20. Mar 11, 20244 EDGAR

The 203 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 11, 2024Merck & Co., Inc.10% ownerBuy21,397,205$23.00$492.1MForm 4
Oct 25, 2023HUNT RONALDDirectorBuy1,543,500Form 4
Oct 25, 2023Lathi Vijay KDirectorBuy1,543,500Form 4
Mar 23, 2023HUNT RONALDDirectorBuy10,000$1,000.00$10.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$125.2M 2023–2023
Money received by yearMoney received by year, 2023–2023: $125.2M in all. Private raises (Form D) $125.2M.$0$50M$100M$150M2023 · Private raises (Form D): $125.2M2023
Figures by year
YearPrivate raises (Form D)Total
2023$125.2M$125.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 25, 2023Raised $100.2 million in a private offering of equity30 Form D: 18 investors so far Form D
  2. Mar 23, 2023Raised $25 million in a private offering of equity67 Form D: 6 investors so far Form D

SEC filer profile

How Harpoon Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHarpoon Therapeutics, Inc.1
  • CIK0001708493
  • Employer ID (EIN)47-34586931
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address611 Gateway Boulevard, Suite 400, South San Francisco, CA 940801
  • Phone(650) 443-74001
  • Shares outstanding16,932,272 as of Oct 31, 202310
  • Public float$26.8M as of Jun 30, 20224
  • On EDGAR sinceJun 6, 20171
  • Filings433 in all: 4 (181), 8-K (61), 3 (26), 10-Q (15), SC 13G (15), SC 13G/A (15), 4/A (12), SC 13D/A (11)1
    All 40 form types

    CORRESP (9), DEFA14A (9), EFFECT (8), S-8 (7), S-8 POS (7), UPLOAD (6), 10-K (5), 424B5 (4), D (4), DEF 14A (4), S-3 (4), SC 13D (4), POS AM (3), S-1/A (3), 424B3 (2), DFAN14A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), CT ORDER (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), PRE 14A (1), PREM14A (1), S-1 (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Mar 11, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68